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Background: Type 2 diabetes, also known non-insulin-dependent diabetes, is the most prevalent type of the
disease and involves defects in the secretion and action of insulin. The aim of the proposed study is to evaluate
the efficacy of pre-exercise low-level laser therapy (LLLT) on muscle performance of the quadriceps femoris in
individuals with type 2 diabetes.
Methods/Design: A double-blind, randomized, controlled clinical trial will be carried out in two treatment phases.
In the first phase, quadriceps muscle performance will be evaluated using an isokinetic dynamometer and the
levels of creatine kinase and lactate dehydrogenase (biochemical markers of muscle damage) will be determined.
The participants will then be allocated to four LLLT groups through a randomization process using opaque envelopes:
Group A (4 Joules), Group B (6 Joules), Group C (8 Joules) and Group D (0 Joules; placebo). Following the administration
of LLLT, the participants will be submitted to an isokinetic eccentric muscle fatigue protocol involving the quadriceps
muscle bilaterally. Muscle performance and biochemical markers of muscle damage will be evaluated again
immediately after as well as 24 and 48 hours after the experimental protocol. One week after the last evaluation the
second phase will begin, during which Groups A, B and C will receive the LLLT protocol that achieved the best
muscle performance in phase 1 for a period of 4 weeks. At the end of this period, muscle performance will be
evaluated again. The protocol for this study is registered with the World Health Organization under Universal
Trial Number U1111-1146-7109.
Discussion: The purpose of this randomized clinical trial is to evaluate the efficacy of pre-exercise LLLT on the
performance of the quadriceps muscle (peak torque, total muscle work, maximum power and fatigue index – normalized
by body mass) in individuals with DM-2. The study will support the practice of evidence-based to the use of LLLT
in improving muscle performance in Individuals with DM-2. Data will be published after the study is completed.
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Diabetes mellitus (DM) is a heterogeneous group of meta-
bolic disorders characterized by hyperglycemia stemming
from defects in the secretion and/or action of insulin.
Type 2 DM (DM-2), also known non-insulin-dependent
diabetes, accounts for more than 90% of cases and is char-
acterized by insulin resistance and a reduction in insulin-
producing β cells in the pancreas as a result of interactions
among genetic polymorphisms, obesity, a sedentary life-
style and the ageing process [1,2].
Diet, drug therapy and physical exercise are highly rec-
ommended for weight loss among individuals with DM-
2 to improve blood sugar control and avoid the loss of
muscle mass [3]. Cardiovascular and strength training
are recommended to enhance physical fitness, muscle
mass and strength in these individuals [4]. Training pro-
grams founded on resistance exercises are considered
safe and well tolerated by individuals with DM-2, includ-
ing elderly individuals [5]. Indeed, resistance training is
more efficacious than moderate weight loss for improve-
ments in glycated hemoglobin, which is a commonly
employed reference to determine the degree of blood
sugar control in individuals with DM [5,6].
Muscle quality is reported to be significantly lower in
patients with DM-2 than individuals without this disease
[7,8]. Thus, such patients often encounter difficulties
when performing exercise programs which increases the
risk of diminished physical function and the occurrence of
comorbidities and even death [9-11]. Patients with DM-2
seem to activate a limited number of the motor units re-
sponsible for muscle contractions, which may be related
to the denervation of muscle fibers and/or the increase in
intramuscular fat tissue [12].
Low-level laser therapy (LLLT) is a recent option for
enhancing muscle performance and is founded on the
application of light in the range of 1 to 500 mW on a
given region of the body for the promotion of tissue re-
generation, the modulation of inflammation, pain relief
[13] and improvements in muscle fatigue. LLLT is re-
ported to optimize muscle performance in both animals
[14-17] and humans [18,19]. LLLT also improves levels
of biological markers directly related to the recovery of
the musculoskeletal system when applied before [19],
during [20] or after [21] the execution of physical exercise.
This therapeutic modality seems to improve muscle per-
formance via the energy metabolism in cells by stimula-
ting photochemical events and enhancing mitochondrial
function in muscle cells [22]. The structural changes in
the mitochondria (size) promoted by LLLT lead to an im-
provement in cell respiration and the formation of adeno-
sine triphosphate, which provides energy to the cells [23].
LLLT may be useful in individuals with DM-2, allowing im-
provements in muscle fatigue and the potentiation of
muscle function, with a consequent improvement inexercise capacity and a reduction in the emergence of
comorbidities such as diabetic neuropathy.
The hypothesis of the proposed study is that pre-
exercise LLLT is capable of improving eccentric muscle
performance in individuals with DM-2. If this improve-
ment is confirmed, the use of LLLT can favor the exe-
cution of physical exercise and activities of daily living
among such patients and avoid the emergence of co-
morbidities that are common to this disease. LLLT
could be widely used in the clinical setting and become
an easy-to-administer treatment strategy of consider-
able value. Moreover, the scientific community is in
need of further clinical trials on LLLT involving human
subjects for the definition of application parameters,
mechanisms of action and the long-term effect on ske-
letal muscle performance.
The aim of the proposed study is to evaluate the effi-
cacy of pre-exercise LLLT on the performance of the
quadriceps femoris (peak torque, total muscle work,
maximum power and fatigue index normalized by body
mass) in individuals with DM-2.
Methods/Design
Overview of research design
A double-blind, randomized, controlled trial will be
carried out. The participants will be allocated to four
LLLT groups through a randomization process using
opaque envelopes: Group A (4 Joules), Group B (6
Joules), Group C (8 Joules) and Group D (0 Joules; pla-
cebo). Evaluations will be performed using multidi-
mensional questionnaire, self-perceived fatigue (visual
analog scale for fatigue (VAS-F) and Item 2.2 on the
WHOQOL-100), Lower Extremity Functional Scale
(LEFS), Diabetes Quality of Life (DQOL) measure,
Problem Areas in Diabetes (PAID) scale, WHOQOL-
BREF, Patient Specific Functional Scale (PSFS), functional
evaluations (isokinetic dynamometer, sit-and-stand
test, timed up-and-go test (TUGT), functional reach
test (FRT)) and blood collection for the assessment
of markers of muscle damage and the capillary gly-
cemia test.
The study will be divided into six evaluations and two
treatment phases to which all individuals will be submitted.
Evaluation 1
After screening, individuals who meet the eligibility cri-
teria will undergo an initial evaluation involving the
multidimensional questionnaire, LEFS, DQOL, PAID,
WHOQOL-BREF, PSFS, sit-and-stand test, TUGT and
FRT. On a separate day, scheduled based on the avail-
ability of the individuals, the blood collection, capillary
glycemia test and isokinetic dynamometry (maximum
voluntary isometric contraction (MVIC) of the quadri-
ceps muscle) will be performed.
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Immediately after randomization, treatment will be per-
formed with the administration of the LLLT protocol for
the respective groups on the quadriceps muscle bilat-
erally (alternating legs).
Evaluation 2
Immediately following LLLT, the groups will perform
the isokinetic eccentric muscle fatigue protocol for the
quadriceps muscle bilaterally (alternating legs).
Evaluation 3
Immediately after the exercise protocol, blood collection,
the capillary glycemia test and isokinetic dynamometry
(MVIC of the quadriceps muscle bilaterally (alternating
legs)) will be performed.
Evaluation 4
Twenty-four hours after the exercise protocol, blood col-
lection, the capillary glycemia test and isokinetic dyna-
mometry (MVIC of the quadriceps muscle bilaterally
(alternating legs)) will be performed.
Evaluation 5
Forty-eight hours after the exercise protocol, blood col-
lection, the capillary glycemia test and isokinetic dyna-
mometry (MVIC of the quadriceps muscle bilaterally
(alternating legs)) will be performed.
Treatment phase 2
One week after Evaluation 5, Groups A, B and C will re-
ceive the LLLT protocol that achieved the best muscle per-
formance in phase 1 and Group D will receive placebo
LLLT three sessions per week for a period of 4 weeks (total
of 12 sessions).
Evaluation 6
Immediately after the 12th session, evaluations will be
performed using the LEFS, DQOL, PAID, WHOQOL-
BREF, PSFS, sit-and-stand test, TUGT, FRT and MVIC
of the quadriceps muscle bilaterally (alternating legs)
(Additional files 1 and 2).
Blinding
The participants will be blinded to the allocation to the
different groups. One researcher will be in charge of the
randomization process and will program the laser device
based on the results of the randomization. A second re-
searcher will perform the LLLT and will be blinded to
the doses and respective groups. These researchers will
not participate in any of the evaluation phases, which
will be performed by a third researcher blinded to the al-
location of the subjects to the different groups. When
blood collection is involved, the evaluations will beperformed by an experienced, trained nurse, who will
only participate in these evaluations. The statistician will
be blinded to the group allocation until completion of
the statistical analyses.
Inclusion criteria
Diagnosis of DM-2 confirmed by the participant’s phy-
sician; age between 30 and 70 years; either gender; suf-
ficient cognitive level for understanding the procedures and
following the instructions; and agreement to participate in
the study by signing of a statement of informed consent
after receiving clarifications regarding the objectives.
Exclusion criteria
Diagnosis of cardiovascular disorder; hepatic diseases;
pernicious anemia; diagnosis of diabetic neuropathy; oc-
currence of skin lesion or local infection over the quad-
riceps muscle; history of skeletal muscle injury in
previous six months or during the execution of the
study; inability to perform exercise protocol or undergo
evaluations in a satisfactory manner; current practice of
regular physical activity; and chronic joint disease in
lower limbs. Exclusion criteria will be determined by ac-
cess to medical history of individuals.
Ethical considerations
The proposed study received approval from the local
Human Research Ethics Committee under process number
n° 164549 dated 5 December 2012. The study will be con-
ducted in compliance with the norms that regulate research
involving human subjects contained in Resolution n° 196/
97 of the Brazilian National Health Council. The study
is registered with the World Health Organization under
Universal Trial Number U1111-1146-7109.
All participants will be informed regarding the objec-
tives and procedures of the study and will be asked to sign
a statement of informed consent agreeing to participate.
Procedures
Questionnaires
At the beginning (Evaluation 1) and end (Evaluation 6) of
the study, the following questionnaires will be employed:
– A multidimensional questionnaire drafted by the
researchers addressing clinical and socio-demographic
variables (gender, weight, height, age, marital status,
time elapsed since the diagnosis of DM-2, schooling,
other diagnosed conditions, medications in use and
dose of medications in use).
– LEFS: developed in English to evaluate
musculoskeletal disorders of the lower limbs [24],
the LEFS consists of 20 items addressing different
activities. Each item has a five-option response scale,
which is scored as follows: 0 (extreme difficulty or
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(moderate difficulty); 3 (a little bit of difficulty); and
4 (no difficulty). The maximum score is 80 points,
with lower scores denoting greater difficulty [25].
The LEFS has been adapted and validated for
Portuguese, with Cronbach’s alpha = 0.95 [25].
– DQOL: this questionnaire has 46 multiple-choice
items for the evaluation of quality of life among
individuals with diabetes and is made up of four
subscales: satisfaction, impact, social/occupational
worries and worries related specifically to diabetes.
The response options are organized on a five-point
Likert scale: 1 = very satisfied; 2 = quite satisfied;
3 = moderately satisfied; 4 = somewhat dissatisfied;
and 5 = completely dissatisfied. For the impact and
worries subscales, the items are scored as follows:
1 = never; 2 = rarely; 3 = sometimes; 4 = often; and
5 = always. Lower scores denote a better quality
of life [26]. The DQOL has been translated and
validated for Portuguese and demonstrates adequate
reliability and validity for patients with DM-2 [26].
– PAID: questionnaire composed of 20 items on the
emotional state of individuals with DM (types 1 and 2).
Each item has a five-point Likert response scale:
0 = not a problem; 1 = small problem; 2 = moderate
problem; 3 = nearly a serious problem; and 4 =
serious problem. The score ranges from 0 to 100
points, with higher scores denoting a greater degree
of emotional suffering [27]. The Portuguese version
will be used in the proposed study, which has a
Cronbach’s alpha = 0.93 for patients with DM-2 [28].
– WHOQOL-BREF: this questionnaire is the short
form of the WHOQOL-100, which was developed
by the Quality of Life workgroup of the World
Health Organization and has previously been used
on individuals with DM-2 [29]. The questionnaire
is made up of 26 items, two on global and general
health and the others distributed among four
subscales: physical health, psychological health,
social relations and environment. Each item is
scored using a Likert scale (1 to 5 points). The results
are transformed into a linear scale (0 to 100), with
higher scores denoting a better quality of life [30].
The Brazilian version of the WHOQOL-BREF has
demonstrated satisfactory internal consistency for
both the items and subscales and is a useful tool for
the evaluation of quality of life in the Brazilian
population [31]. This questionnaire will be
administered during Evaluations 1 and 6 and will
also be administered by telephone 3 and 6 months
after Evaluation 6.
– PSFS: the aim of this self-report scale is to evaluate
functional changes, especially those related to the
musculoskeletal system. This scale can be used forany part of the body in individuals with different
degrees of functionality and different diseases.
Function is self-rated on five activities the individual
considers important and is having difficulty performing
or is unable to perform. Each activity identified by
the individual is rated using an 11-point Likert scale
(0–11 points), for which higher scores denote greater
functionality [32].
– Self-perceived fatigue: subjective fatigue following
the MVIC and isokinetic eccentric exercise protocol
of the quadriceps muscle will be determined using
the VAS-F and item F2.2 on the WHOQOL-100
(physical subscale). For the VAS-F, a color scale
measuring 50 cm in length will be printed on a piece
of paper, beginning with light blue (minimum) and
proceeding to intense red (maximum). The individual
will mark their subjective evaluation of muscle fatigue
on the scale. On the other side of the card, the
examiner will have access to a numeric scale ranging
from 0 (minimum) to 10 (maximum) and record the
value corresponding to the subject’s mark on the
opposite side. Only the examiner will have access to
the numeric scale [33,34].
All questionnaires will be administered in a reserved
room and are to be filled out completely. If an individual
refuses or is unable to cooperate, Examiner 2 will mark
“NR” (no record) in capital letters on the exam. To avoid
hurried responses from the participants, no time con-
straints will be applied.
Functional assessment tests
– Sit-and-stand test: a standardized chair will be used
for all individuals, with an adjustable height to
maintain the knees flexed at 90° and no arm rests. Sit-
and-stand was chosen due the fact that this move-
ment is one of the activities of daily living of greater
demand in terms of mechanical aspects [35]. The
individual will be instructed to sit down and stand up
from the chair five times. The execution time will be
recorded with the aid of a stopwatch (OREGON© -
Oregon Scientific Brasil LTDA – http://www.oregon
scientific.com - Avenida Ibirapuera, 2907 – São Paulo/
SP. Phone: 55 11 50952329).
– TUGT: this test has been used to evaluate function
in individuals with DM-2 [36]. The TUGT measures
functional mobility based on the time required to
stand up from a chair, walk three meters, turn
around, walk back to the chair and sit down again.
The test will begin with the verbal command “go”
and will end when the participant is once again
seated in the chair. The execution time will be re-
corded with the aid of a stopwatch (OREGON©).
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to become familiarized with the procedure and the
second trial will be used to record the execution
time. A standardized chair will be used for all
individuals, with an adjustable height to maintain
the knees flexed at 90° and no arm rests [37]. The
following are the reference parameters for this test:
10 seconds for healthy, independent adults with no
risk of falls; 11 to 20 seconds for elderly individuals
with disability or frailty; and greater than 20 seconds
for elderly individuals with important mobility
impairment and a risk of falls [38].
– FRT: this test measures the maximum distance an
individual can reach forward beyond the length of
his/her arm while maintaining a fixed standing base.
The FRT has been used to determine movement
strategies in patients with DM [39]. A reach less
than 15 cm indicates frailty and an eminent risk of
falls [40]. A metric tape will be attached to the wall
parallel to the ground at the height of the
individual’s acromion. The participant will be
barefoot with the feet aligned and standing next to
the beginning of the tape measure, with the wrists in
a neutral position, elbows extended and the shoulder
flexed at 90°. The individual will be instructed to
lean forward without touching the tape. The
movement of the wrist over the tape will be read
three times and the mean will be used for the
analysis [39].
Blood collection
Blood samples (10 ml) will be collected through the ante-
cubital vein by an experienced nurse. One hour after col-
lection, the samples will be centrifuged at 3,000 rpm for
20 minutes. Pipettes will be used to transport the serum
to Eppendorf® tubes (Eppendorf, Hamburg, Germany)
which will be stored at −80°Cuntil analysis. Enzyme ac-
tivity of creatine kinase (CK; CK-MB, CK-MM and CK-
BB) and lactate dehydrogenase (LDH; LHD1,2,3,4,5) will
be analyzed. The biochemical markers of muscle dam-
age will be analyzed in a clinical laboratory [41,42].
Capillary glycemia will be monitored by the individuals
themselves. The use of the equipment will be explained
prior to the procedure. Blood will be taken from the
palm side of the tip of the third finger on the right hand
using a digital blood sugar meter (Accu-Chek® Performa
nano; Roche Diagnosis (9115 Hague Road, Indianapolis,
United States) and lancet (Accu-Chek® multiclix; Roche
Diagnostics (9115 Hague Road, Indianapolis, United
States)). The lancet will be standardized at the deepest
penetration (number 5). The measure of capillary gly-
cemia and fast, highly precise digital monitors is cur-
rently considered the gold standard for at-home blood
sugar control in patients with DM and will be used inthe present study to determine the oscillation in blood
sugar in the different phases of the study [43].
Isokinetic dynamometry
The Biodex System 3 Pro isokinetic dynamometer (Bio-
dex Medical System System 4, Biodex Medical Systems,
Inc., Shirley, NY, USA) will be used for the eccentric fa-
tigue protocol and MVIC of the quadriceps muscle bilat-
erally (alternating sides). This device is considered
reliable and reproducible for muscle evaluations [44]
and has been used on patients with different diseases
such as heart failure [45], osteoarthritis [46] and spinal
cord injury [47], as well as on different populations ran-
ging from children [46] to the elderly [47-49]. In the
proposed study, peak torque (maximum generation of
force by the muscle) and the Muscle Fatigue Index
[50,51] will be analyzed.
The volunteer will first perform three 60-second sets
of active stretching of the quadriceps muscle bilaterally,
followed by warm up consisting of pedaling a stationary
bike (Inbramed®, Inbramed, Porto Alegre, RS, Brazil) at
100 rpm for 5 minutes without load. The volunteer will
then be positioned on the isokinetic dynamometer (pre-
viously calibrated following the instructions in the man-
ual), duly aligned and stabilized by straps to avoid
compensatory movements. The rotation axis of the
dynamometer will be aligned with the movement axis of
the knee being evaluated at the level of the lateral epi-
condyle of the femur. Chair height and base, distance of
the support, accessory level and base of the dynamom-
eter will be adjusted to the needs of each individual.
During the test, the volunteer will be instructed to cross
his/her arms over the chest and the axis of the dyna-
mometer will be positioned parallel to the center of the
knee.
MVIC will consist of three 5-second isometric con-
tractions of the knee extensors (Figure 1). The greatest
torque of the three contractions (peak torque) will be
used in the statistical analysis. This variable was chosen
based on the fact that it reflects the maximum gener-
ation of force by the muscle [52]. The instructions will
be given first and the volunteers will receive verbal en-
couragement during the MVIC.
The volunteers will perform the isokinetic eccentric
fatigue protocol for the quadriceps muscle bilaterally
(Figure 2), which will consist of 75 isokinetic eccentric
contractions of the knee extensors (5 sets of 15 repeti-
tions with a 30-second rest period between sets) at a
velocity of 60°.sec−1 in both the eccentric and concen-
tric phases, with a 60° range of motion (between 90°
and 30° of knee flexion) for each leg. At each contrac-
tion, the dynamometer will automatically (passively)
position the knee at 30° and will then flex the knee until
reaching 90°. The volunteers will be instructed to resist
Figure 1 Realization of isokinetic dynamometry maximum
voluntary isometric contraction (MVIC) of the
quadriceps muscle.
Figure 2 Realization of the isokinetic eccentric fatigue protocol for th
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imum force. The instructions will be given first and the
volunteers will receive verbal encouragement throughout
the exercise. This protocol has proven to be efficient and
reliable for exercise-induced muscle damage [19].
The order on both the MVIC and isokinetic eccentric
fatigue protocol for the quadriceps muscles will be
determined randomly by lots using sealed, opaque
envelopes.
Low-level laser therapy protocol
A five-diode cluster laser device (810 nm and 200 mW
for each diode) (THOR Photomedicine®, Thor Photo-
medicine, Chesham, UK) will be used for LLLT. For
the placebo group, a laser device that produces the
same characteristics (cluster) will be used, but will
not emit Joules. The LLLT protocol will be perfor-
med with the cluster in direct contact with the skin
at six different sites over the quadriceps muscle (2
medial, 2 lateral and 2 central), totaling 30 points on
each leg. The volunteers will be distributed in the fol-
lowing groups:
– Group A – 4 Joules per point (irradiation time:
20 seconds), 120 Joules of total energy irradiated over
the muscle with 120 seconds of total irradiation time.e quadriceps muscle.
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30 seconds), 180 Joules of total energy irradiated over
the muscle with 180 seconds of total irradiation time.
– Group C – 8 Joules per point (irradiation time:
40 seconds), 240 Joules of total energy irradiated over
the muscle with 240 seconds of total irradiation time.
– Group D – 0 Joules per point (“irradiation” time:
40 seconds), 0 Joules of total energy irradiated over the
muscle with 240 seconds of total “irradiation” time.
The order of the LLLT protocol on the quadriceps mus-
cles will be determined randomly by lots using sealed,
opaque envelopes.Data analysis
Peak torque determined by the isokinetic dynamometer will
be the primary outcome and CK and LDH activity deter-
mined from the blood samples will be the secondary out-
comes. The Shapiro-Wilk test will be used to test the data
with regard to Gaussian distribution. Data will be expressed
as mean and standard deviation values. Two-way repeated-
measures analysis of variance with the post hoc Bonferroni
test will be used for inter-group and intra-group compari-
sons. The level of significance will be set to 5% (P < 0.05)
for all comparisons. Statistical analysis will be performed
using the SPSS program, version 13.0 (Chicago, IL, USA).Discussion
The purpose of this randomized clinical trial is to evaluate
the efficacy of pre-exercise LLLT on the performance of
the quadriceps muscle (peak torque, total muscle work,
maximum power and fatigue index – normalized by body
mass) in individuals with DM-2. The study will support
the practice of evidence-based to the use of LLLT in im-
proving muscle performance in Individuals with DM-2.
Data will be published after the study is completed.Trial status
Patient recruitment is currently underway.Additional files
Additional file 1: Flowchart phase 1.
Additional file 2: Flowchart phase 2.Abbreviations
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